| abstract |
Disclosed are benzamide compounds with a substituted sulfonyl group on the amide and substituted heteroalkyl group at the 4 position of the benzamideof formula (I) where the substituents are as disclosed in the specification. Examples of these compounds are: 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-2-(1H-indol-5-yloxy)-N-(2-naphthylsulfonyl) benzamide; 4-{ 4-[(4’-chlorobiphenyl-2-yl)methyl]piperazin-1-yl} -N-[(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)sulfonyl]benzamide; 4-{ 4-[(4’-chlorobiphenyl-2-yl)methyl]piperazin-1-yl} -N-[(6-chloro-1,1-dioxido-2H-1,2,4-benzothiadiazin-7-yl)sulfonyl]benzamide and 4-{ 4-[(4’-chlorobiphenyl-2-yl)methyl]piperazin-1-yl} -N-[(5,5,8,8-tetramethyl-5,6,7,8- tetrahydronaphthalen-2-yl)sulfonyl]benzamide. The compounds inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. Also disclosed is a composition comprising one of the compounds and the use of one of the compounds for the manufacture of a medicament for treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukaemia, colorectal cancer, oesophageal cancer, hepatocellular cancer, lymphoblastic leukaemia, follicular lymphoma, a lymphoid malignancy of T-cell or B-cell origin, melanoma, myelogenous leukaemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer. |